We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Human Interferon-Induced Protein Blocks Zika Virus Infection

By LabMedica International staff writers
Posted on 15 Jun 2016
Print article
Image: IFITM3 blocks Zika virus infection. When human cells are exposed to Zika virus they are overwhelming infected, as seen by the large number of green cells (left panel). When IFITM3 levels were boosted in these cells, the same amount of virus was prevented from replicating (right panel) (Photo courtesy of Brass Lab, University of Massachusetts Medical School).
Image: IFITM3 blocks Zika virus infection. When human cells are exposed to Zika virus they are overwhelming infected, as seen by the large number of green cells (left panel). When IFITM3 levels were boosted in these cells, the same amount of virus was prevented from replicating (right panel) (Photo courtesy of Brass Lab, University of Massachusetts Medical School).
A team of molecular virologists has shown that the human protein IFITM3 (interferon-induced protein 3) inhibits Zika virus infection early in the viral life cycle and can prevent Zika-virus-induced cell death.

The IFITM family of restriction factors has been found to inhibit the replication of a broad range of viruses, including the closely related flaviruses West Nile virus and dengue virus.

Investigators at the University of Massachusetts Medical School (Worcester, USA) used tools and assays that had been developed for studying IFITM3 in dengue and influenza virus infections to evaluate the effect of this factor on Zika virus.

They reported in the June 3, 2016, online edition of the journal Cell Reports that IFITM3 and the closely related IFITM1 inhibited Zika virus infection early in the viral life cycle. Moreover, IFITM3 was shown to prevent Zika-virus-induced cell death.

"We simply adapted the technology we had developed over the last four years working with dengue, influenza, and other viruses to begin work on Zika virus," said senior author Dr. Abraham Brass, assistant professor of microbiology and physiological systems at the University of Massachusetts Medical School.

"This work represents the first look at how our cells defend themselves against Zika virus' attack," said Dr. Brass. "Our results show that Zika virus has a weakness that we could potentially exploit to prevent or stop infection. A lot of data by us and others in the field has shown that IFITM3 has a big impact on blocking many emerging viruses such as dengue, Zika, and Ebola. Given our recent results with Zika virus, it is now even more important that we work to find out how IFITM3 is blocking these viruses, and use that knowledge to prevent and treat infections."

Related Links:
University of Massachusetts Medical School


New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The HelioLiver Dx test has met the coprimary and secondary study endpoints in the CLiMB trial (Photo courtesy of Helio Genomics)

Blood-Based Test Outperforms Ultrasound in Early Liver Cancer Detection

Patients with liver cirrhosis and chronic hepatitis B are at a higher risk for developing hepatocellular carcinoma (HCC), the most prevalent type of liver cancer. The American Association for the Study... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The POC PCR test shortens time for STI test results (Photo courtesy of Visby Medical)

POC STI Test Shortens Time from ED Arrival to Test Results

In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
LGC Clinical Diagnostics